TL;DR
Researchers have developed a novel "autologous humanized PDX model" using MISTRG6 mice that effectively recapitulates the human tumor microenvironment (TME). This system allows for the study of individual patient tumor-immune interactions and shows promise for preclinical drug testing by enabling the growth of patient-derived tumors within mice that have been engrafted with the patient's own immune system.
What Problem Does This Paper Address?
Modeling the human tumor microenvironment (TME) is crucial for understanding cancer progression and developing effective immunotherapies. However, existing preclinical models face significant challenges:
- Interspecies Differences: Mouse models often don't accurately reflect human immune responses due to fundamental differences between mouse and human immune cells and their interactions.
- Limited Humanization Efficiency: Previous attempts to humanize mice with hematopoietic stem and progenitor cells (HSPCs) have been inefficient, requiring large numbers of cells or using cells from fetal/neonatal donors, which don't fully represent adult immune systems. This also leads to mismatched immune responses between the donor cells and the tumor.
- Lack of Patient Specificity: Current models often fail to capture the unique genetic makeup and tumor heterogeneity of individual patients, hindering personalized treatment strategies.
This paper aims to bridge these gaps by creating a fully genetically matched, autologous system that models the TME from individual patients with solid tumors, enabling more accurate preclinical drug testing.
Methods
The core of this study revolves around a sophisticated mouse model and experimental approach:
- MISTRG6 Mice: These mice are genetically engineered (humanized) to express human versions of key immune-related genes (M-CSF, CSF2/IL3, SIRPA, THPO) and, crucially for this study, human IL-6. This humanization enhances the development of various human immune cell types, including innate immune cells.
- Autologous Hematopoietic Stem and Progenitor Cell (HSPC) Engraftment: The researchers used CD34+ HSPCs isolated from bone marrow aspirates of adult cancer patients. These cells were injected into the MISTRG6 mice, allowing them to reconstitute the mouse's immune system with human cells. The MISTRG6 strain demonstrated significantly improved engraftment efficiency compared to previous MISTRG models, even with lower numbers of HSPCs.
- Patient-Derived Xenograft (PDX) Implantation: After successful human immune cell engraftment, patient-derived tumor tissue (PDX) from the same individual was implanted into the mice. This created a fully autologous system where the patient's tumor grew within a mouse populated by the patient's own human immune system.
- Single-Cell Transcriptomics (scRNA-seq): This powerful technique was used to analyze the gene expression profiles of individual cells from both the blood and the tumor microenvironment of the humanized mice. This allowed for detailed characterization of the diverse immune cell populations present and their functional states.
- Whole-Exome Sequencing (WES): WES was performed on tumor samples to compare the mutational landscape of the patient's original tumor, PDXs grown in non-humanized mice, and PDXs grown in the autologous humanized mice. This helped assess how well the model recapitulated the patient's tumor genetics.
- Functional Inhibition Studies: To validate the role of specific TME components, the researchers used bevacizumab, an anti-human VEGF-A antibody, to block VEGF-A signaling in the autologous PDX models and observed its effect on tumor growth.
Datasets
- Human Patient Samples: Bone marrow aspirates and tumor tissues were collected from patients with various solid tumors, including melanoma, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), and head and neck squamous cell carcinoma (HNSCC).
- Human HSPCs: CD34+ HSPCs were isolated from bone marrow aspirates of these patients.
- PDX Tissues: Patient-derived xenograft tissues were generated from the collected tumor samples.
- Mouse Blood and Tumor Samples: Samples were collected from MISTRG6 mice at various time points after HSPC engraftment and PDX implantation for scRNA-seq and histological analysis.
- Reference Data: Whole-exome sequencing data from the patient's primary tumor and a derived cell line were used for comparison.
No new benchmarks were introduced; rather, the study leverages existing PDX models and humanized mouse technology to create a more advanced, patient-specific platform.
Key Insights and Ideas
- Human IL-6 is Key for Adult HSPC Engraftment: Humanizing the IL-6 locus in MISTRG6 mice significantly improved the efficiency of engraftment with adult HSPCs, making it feasible to model individual patient immune systems. This is a critical advancement over previous models.
- Autologous System Mimics Patient TME: The combination of autologous HSPC engraftment and PDX implantation successfully recreated a human TME within the mouse, complete with diverse innate and adaptive immune cell populations.
- VEGF-A Drives Enhanced Tumor Growth: The study identified a prominent VEGF-A signature in myeloid cells within the TME of these autologous models. Inhibiting human VEGF-A with bevacizumab significantly reduced tumor growth, highlighting VEGF-A's critical role in this model and its potential as a therapeutic target.
- Immune Cell Plasticity and Activation: Single-cell transcriptomics revealed activated and even "exhausted-like" CD8 T cell populations within the TME, mirroring observations in human cancer patients. This suggests the model captures important aspects of immune responses to tumors.
- Preservation of Tumor Heterogeneity: Whole-exome sequencing demonstrated that the autologous PDX models largely preserved the somatic mutations present in the original patient tumors, underscoring their utility for studying tumor evolution and drug response.
Key Results
- Enhanced Engraftment: MISTRG6 mice showed significantly higher proportions of human hematopoietic cells in peripheral blood and various tissues compared to NSG and MISTRG mice, even with fewer HSPCs.
- Successful PDX Growth: Autologous PDX tumors in MISTRG6 mice grew larger than those in non-engrafted littermates, indicating a pro-tumorigenic role for the human immune microenvironment.
- Diverse Immune Infiltration: Human immune cells, including CD3+ T cells, CD14+ and HLA-DR+ myeloid cells, were found to infiltrate the PDX tumors deeply.
- VEGF-A Inhibition Efficacy: Treatment with bevacizumab (anti-human VEGF-A) significantly abrogated the enhanced tumor growth observed in autologously engrafted mice, demonstrating the model's utility for testing targeted therapies.
- Recapitulation of Tumor Genetics: WES confirmed that autologous PDX models shared a high number of somatic mutations with the original patient tumors.
Limitations and Future Work
- Lack of Human Neutrophils, Basophils, and Eosinophils: Like most humanized mouse models, MISTRG6 mice do not fully develop these specific human immune cell types. Further research is needed to identify the genetic requirements for their development.
- PDX Generation Variability: Not all fresh tumor tissue samples reliably generate PDXs that grow robustly, and the process of PDX generation can select for more aggressive tumor phenotypes.
- HSPC Yield Variability: Bone marrow aspiration yields can vary, and in rare cases, insufficient HSPCs may be obtained.
- Chronological Lag: The time required for PDX generation can introduce a delay between tissue collection and the start of autologous modeling, potentially limiting its use for predicting immediate responses to primary therapies. However, the authors suggest it can be valuable for modeling second or third-line therapies.
- Absence of Human Thymus: The model lacks a human thymus, meaning T cells are selected in the mouse thymus. While the data show activated CD8 T cells, further investigation into human MHC presentation on DCs and T cell activation mechanisms is warranted.
Future work will likely focus on further refining the humanization of MISTRG6 mice, expanding the range of tumor types modeled, and utilizing this platform for prospective co-clinical trials to test novel immunotherapies and targeted agents.
Summary updated